Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Intensity Modulated Radiotherapy Treatments
RADIATION
2 trials
Sponsors
UNC Lineberger Comprehensive Cancer Center
Conditions
Carcinoma, Squamous Cell of Head and Neck
Digestive Organs--Diseases
Larynx
Lip
Oral Cancer
Phase 1
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
Completed
NCT02585973
UNC Lineberger Comprehensive Cancer Center
Carcinoma, Squamous Cell of Head and Neck
Start: 2015-10-26
End: 2021-06-23
Updated: 2021-06-29
Phase 2
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
Active, not recruiting
NCT03529422
UNC Lineberger Comprehensive Cancer Center
Digestive Organs--Diseases, Larynx, Lip +1
Start: 2019-10-07
End: 2026-05-06
Updated: 2025-07-20
Related Papers
Phase I study of durvalumab and tremelimumab together with radiotherapy for the adjuvant treatment of intermediate-risk head and neck squamous cell carcinoma.
Journal of Clinical Oncology
2019-03-10
1 citations
Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma.
Journal of Clinical Oncology
2016-05-20
6 citations